Anakinra Shows Promise for Treating Patients With Rheumatoid Arthritis

McIntosh, Tera; Freeman, Thomas R.

doi:10.1331/108658002763029661

Cited by 7 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a randomized, doublemasked clinical trial conducted to determine the safety efficacy of anakinra (placebo group, 283; anakinra group, 1116), which allowed inclusion of patients receiving concomitant antirheumatic medications and those with concurrent medical conditions, the proportion of patients developing infections was similar in the anakinra group (26%) and the placebo group (27%) [12][13][14]55,56]. In a randomized, doublemasked clinical trial conducted to determine the safety efficacy of anakinra (placebo group, 283; anakinra group, 1116), which allowed inclusion of patients receiving concomitant antirheumatic medications and those with concurrent medical conditions, the proportion of patients developing infections was similar in the anakinra group (26%) and the placebo group (27%) [12][13][14]55,56].…”

Section: Interleukin-1 Inhibitormentioning

confidence: 99%

Infectious complications of biologic treatments of rheumatoid arthritis

Mohan¹,

Coté²,

Siegel³

et al. 2003

Current Opinion in Rheumatology

View full text Add to dashboard Cite

Agents that block the action of tumor necrosis factor-alpha and recombinant interleukin-1 have been shown to be effective biologic treatment modalities in patients with rheumatoid arthritis. Given the immunosuppressive effects of tumor necrosis factor-alpha and interleukin-1 blockers, infections have emerged as possible complications of using these agents, an observation foreshadowed in prelicensure animal studies. At this time, hundreds of thousands of patients have received these drugs, and a wide variety of infectious complications has been reported, among which reactivation tuberculosis is most notable. Case reports alone, however, do not necessarily reflect a causal association between a therapeutic product and an adverse event. The authors review the infectious complications of the use of these agents as reported in the medical literature from November 2001 through October 2002.

show abstract

Section: Interleukin-1 Inhibitormentioning

confidence: 99%

Infectious complications of biologic treatments of rheumatoid arthritis

Mohan¹,

Coté²,

Siegel³

et al. 2003

Current Opinion in Rheumatology

View full text Add to dashboard Cite

show abstract

“…rhIL-1Ra has much pharmacological importance and acts as a major anti-inflammatory protein; it plays an important role in the treatment of RA [24]. Because of high treatment cost and large requirement of rhIL-1Ra, it is required to establish economical, effective, and easily scalable method for largescale expression and purification of the rhIL-1Ra protein in E. coli.…”

Section: Discussionmentioning

confidence: 99%

Evaluating the autoinduction expression system and one‐step purification for high‐level expression and purification of gallbladder‐derived rhIL‐1Ra

Bashir

Ahmed

Khan

et al. 2016

Biotech and App Biochem

View full text Add to dashboard Cite

Recent advancement in fermentation technologies resulted in the increased yields of recombinant proteins of biopharmaceutical and medicinal importance. Consequently, there is an important task to develop simple and easily scalable methods that can facilitate the production of high-quality recombinant protein. Most of the recent reports described the expression of recombinant human IL-1 receptor antagonist (rhIL-1Ra) in Escherichia coli using isopropyl-β-d-thiogalacto pyranoside (IPTG), a nonmetabolizable and expensive compound, as an expression inducer. In this study, we describe the expression and one-step purification of gallbladder-derived rhIL-1Ra by autoinduction in E. coli. This method includes special media that automatically induce the target protein expression from T7 promoter and allow the production of the target protein in high yield than the conventional IPTG induction method. In addition to fermentation process improvements, one-step purification strategy is essential to make the process economical. We developed a single-step cation exchange chromatography and obtained 300 mg/L of rhIL-1Ra with 98% purity. Purified protein was characterized by SDS-PAGE and Ion exchange HPLC (IEX-HPLC). The described method can be used to scale up the production of rhIL-1Ra and other recombinant proteins.

show abstract

“…There is compelling evidence that IL-1ra plays a critical role in ameliorating the signs and symptoms of rheumatoid arthritis and retarding joint damage (McIntosh & Freeman 2002) and showed a favorable safety profile (Nuki et al 2002). IL-1ra also showed notable functions for treating active ankylosing spondylitis (Tan et al 2004), thus implicating IL-1ra as an important mediator for inflammation.…”

Section: Introductionmentioning

confidence: 99%

On-Column Refolding and Purification of Recombinant Human Interleukin-1 Receptor Antagonist (rHuIL-1ra) Expressed as Inclusion Body in Escherichia coli

Tan

Dan²,

Gong³

et al. 2005

Biotechnol Lett

View full text Add to dashboard Cite

Recombinant human interleukin-1 receptor antagonist (rHuIL-1ra) was produced in E. coli as an inclusion body. rHuIL-1ra was purified to Over 98% purity by anion exchange chromatography after on-column refolding. The optimized processes produced more than 2 g pure refolded rHuIL-1ra per 1 l culture, corresponding to a 44% recovery, without an intermediate dialysis step. Refolded rHuIL-1ra had full biological activity with the MTT assay. An intramolecular disulfide linkage in the oxidized recombinant protein was suggested by data from HPLC and non-reducing SDS-PAGE.

show abstract

Anakinra Shows Promise for Treating Patients With Rheumatoid Arthritis

Cited by 7 publications

References 6 publications

Infectious complications of biologic treatments of rheumatoid arthritis

Infectious complications of biologic treatments of rheumatoid arthritis

Evaluating the autoinduction expression system and one‐step purification for high‐level expression and purification of gallbladder‐derived rhIL‐1Ra

On-Column Refolding and Purification of Recombinant Human Interleukin-1 Receptor Antagonist (rHuIL-1ra) Expressed as Inclusion Body in Escherichia coli

Contact Info

Product

Resources

About